OakChart

Werewolf Therapeutics Inc

HOWLHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 10:39 AM ET

0.9899+0.0199 (2.05%)
2026-11-11 16:44 CET
Market cap
47.14 USD m
Revenue, TTM
21.00 USD m
Net income, TTM
-34.61 USD m
Free cash flow, TTM
-30.15 USD m
EPS diluted, TTM
-0.74
P/E
-
Compare

Price

HOWL against its 20, 50 and 200-day averages
2050200earnings
0.400.600.801.00148.4M296.7MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26HOWLclose 0.9920-day 1.0250-day 0.98200-day 0.700.9952w low

17.5% under the 52-week high of 1.20 on 17 Dec 2025. 52-week low 0.27 on 29 Jun 2026. Last 15 sessions, 15.8% high to low

Profile

HOWL
52-week range, 77% of the way up
0.271.20

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.

Employees39
IPOApr 30, 2021
Beta0.55
ATR, 14d0.06
Rel volume0.02
Short float5.33%
Insider own17.84%
Inst own23.04%

Snapshot

6 groups

Valuation

Index-
Market Cap48.11M
Enterprise Value26.12M
Income-34.61M
Sales21.00M
Book/sh0.34
Cash/sh0.45
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees39
IPOApr 30, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S2.29
P/B2.95
P/C2.19
P/FCF-
EV/EBITDA-
EV/Sales1.24
Quick Ratio2.91
Current Ratio2.91
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.74
EPS next Y-0.59
EPS next Q-0.22
EPS this Y33.08%
EPS next Y33.71%
EPS next 5Y-
EPS past 3/5Y10.71% -6.15%
Sales past 3/5Y- -
EPS Y/Y TTM55.37%
Sales Y/Y TTM-100.00%
EPS Q/Q118.88%
Sales Q/Q-
EarningsJul 31 BMO
EPS/Sales Surpr.- -

Ownership

Insider Own17.84%
Insider Trans-28.94%
Inst Own23.04%
Inst Trans27.27%
ROA-59.31%
ROE-119.86%
ROIC-212.45%
Gross Margin82.61%
Oper. Margin-121.78%
Profit Margin-164.82%
SMA20-3.25%
SMA500.70%
SMA20041.82%
Trades-

Technical

Shs Outstand48.60M
Shs Float39.93M
Short Float5.33%
Short Ratio0.32
Short Interest2.13M
52W High1.20 -17.51%
52W Low0.27 266.63%
Volatility5.54% 6.02%
ATR (14)0.06
RSI (14)48.90
Beta0.55
Rel Volume0.02
Avg Volume6.58M
Volume37,756

Performance

Perf Week-9.18%
Perf Month-0.12%
Perf Quarter156.45%
Perf Half Y69.53%
Perf YTD56.26%
Perf Year-12.40%
Perf 3Y-56.96%
Perf 5Y-93.82%
Perf 10Y-
Recom1.00
Target Price4.00
Prev Close0.97
Price0.99
Change %2.05%

Analyst ratings

latest 9 of 9
DateActionAnalystRating changeTargetImplied
Dec 19, 2025DowngradeWWedbushOutperform → Neutral$1+1.0%
Apr 03, 2024InitiatedJJMP SecuritiesMkt Outperform$12+1,112.2%
Aug 24, 2023InitiatedWWedbushOutperform$9+809.2%
Jun 06, 2023ResumedJJefferiesBuy$11 → $12+1,112.2%
Sep 10, 2021InitiatedBBofA SecuritiesBuy$26+2,526.5%
May 25, 2021InitiatedSSVB LeerinkOutperform$29+2,829.6%
May 25, 2021InitiatedJJefferiesBuy$22+2,122.4%
May 25, 2021InitiatedHH.C. WainwrightBuy$32+3,132.6%
May 25, 2021InitiatedEEvercore ISIOutperform$23+2,223.5%

Peers

Mkt cap
TickerCompanyMkt cap
XLOXilio Therapeutics Inc58.00M
CTMXCytomX Therapeutics Inc445.82M
HCWBHCW Biologics Inc2.17M
BOLTBolt Biotherapeutics Inc11.95M
JANXJanux Therapeutics Inc745.20M
NKTRNektar Therapeutics1.31B
STTKShattuck Labs Inc503.35M
ALXOAlx Oncology Holdings Inc151.42M
GTBPGT Biopharma Inc8.22M
IMNNImunon Inc4.46M

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
EVNIN LUKEDirectorJul 07 '26Sale0.31107,42933,3030Jul 08 05:34 PM
EVNIN LUKEDirectorJul 06 '26Sale0.3235,77011,446107,429Jul 08 05:34 PM
MPM Oncology Innovations Fund,ShareholderJul 06 '26Proposed Sale0.3421,1947,214Jul 06 05:19 PM
MPM Asset Management InvestorsShareholderJul 06 '26Proposed Sale0.343,3321,134Jul 06 05:19 PM
MPM Asset Management LLCShareholderJul 06 '26Proposed Sale0.3415,3415,222Jul 06 05:19 PM
UBS Oncology Impact Fund, L.P.ShareholderJul 06 '26Proposed Sale0.3480,14227,280Jul 06 05:18 PM
MPM BioVentures 2014 (B), L.P.ShareholderJul 06 '26Proposed Sale0.346,4592,199Jul 06 05:18 PM
MPM BioVentures 2014, L.P.ShareholderJul 06 '26Proposed Sale0.3496,87332,976Jul 06 05:18 PM
MPM Oncology Innovations Fund,ShareholderJun 29 '26Proposed Sale0.3223,2487,509Jun 29 05:30 PM
MPM Asset Management InvestorsShareholderJun 29 '26Proposed Sale0.323,6571,181Jun 29 05:30 PM
MPM Asset Management LLCShareholderJun 29 '26Proposed Sale0.3216,8305,436Jun 29 05:29 PM
UBS Oncology Impact Fund, L.P.ShareholderJun 29 '26Proposed Sale0.3287,91628,397Jun 29 05:29 PM
MPM BioVentures 2014 (B), L.P.ShareholderJun 29 '26Proposed Sale0.327,0872,289Jun 29 05:29 PM
MPM BioVentures 2014, L.P.ShareholderJun 29 '26Proposed Sale0.32106,26234,323Jun 29 05:29 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 206
  • Werewolf Therapeutics' Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting (GlobeNewswire)
  • Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting (GlobeNewswire) -10.35%
  • Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders? (PR Newswire)
  • Are PSNL, MKTX, BZH, HOWL Obtaining Fair Deals for their Shareholders? (PR Newswire)
  • Werewolf Therapeutics shares surge 120% after Ambros merger and $150 million financing (InvestorsHub) +102.57%
  • Loading…
  • Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement (GlobeNewswire)
  • Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates (GlobeNewswire) -29.44%
  • Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates (GlobeNewswire) +9.68%
  • Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates (GlobeNewswire) -9.54%
  • Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives (GlobeNewswire)
  • Werewolf Therapeutics (HOWL) Eyes 2026 Catalysts Following FDA Guidance and Encouraging INDUKINE Results (Insider Monkey)
  • Werewolf Therapeutics Announces Pipeline and Business Updates (GlobeNewswire) -39.57%
  • Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know (Zacks) -6.36%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-07-310.080--0.2300.00--
2026Q12026-05-07-0.280--0.2840.00--
2025Q42026-03-27-0.200-0.345-0.1730.000.004
2025Q32025-11-04-0.360-0.383-0.3570.000.006
2025Q22025-08-14-0.400-0.468-0.4000.000.005
2025Q12025-05-08-0.400-0.395-0.4040.000.005
2024Q42025-03-11-0.460-0.403-0.4590.000.306
2024Q32024-11-07-0.380-0.405-0.3820.000.716
2024Q22024-08-08-0.430-0.376-0.3961.140.845
2024Q12024-05-03-0.390-0.342-0.3890.741.465
2023Q42024-03-07-0.330-0.424-0.3281.501.945
2023Q32023-11-14-0.230-0.386-0.2325.901.595
2023Q22023-08-10-0.140-0.422-0.1438.083.155
2023Q12023-05-11-0.340-0.480-0.3454.462.034
2022Q42023-03-23-0.390-0.546-0.3887.282.075
2022Q32022-11-10-0.400-0.588-0.4014.973.054

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-8.895--0.9840.00-
2021FY-10.940-6.320-7.3930.000.00
2022FY-1.860-2.078-1.86416.4011.86
2023FY-1.050-1.110-1.04819.9420.37
2024FY-1.630-1.497-1.6341.921.88
2025FY-1.330-1.505-1.6301.900.00
2026FY--0.890--0.00
2027FY--0.590--0.00
2028FY--1.470--0.05
2029FY--0.985--18.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-211000.000.000.00
2026Q3S2026-02-263000.000.000.00
2026Q3S2025-12-164000.000.000.00
2026Q3S2025-11-113000.000.000.00
2026Q3S2025-11-103000.000.000.00
2026Q3S2025-11-093000.000.000.00
2026Q3S2025-11-083000.000.000.00
2026Q3S2025-11-073000.000.000.00
2026Q3S2025-11-063000.000.000.00
2026Q3S2025-11-053000.000.000.00
2026Q3S2025-11-043000.000.000.00
2026Q3S2025-11-033000.000.000.00
2026Q3S2025-11-023000.000.000.00
2026Q3S2025-11-013000.000.000.00

Estimate history

EPS, annual-0.636-0.984-7.393-1.864-1.048-1.634-1.327-0.7385
Period2019202020212022202320242025TTM
EPS, quarterly-0.396-0.382-0.459-0.404-0.4-0.357-0.173-0.2840.076
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00016.40119.9431.885021
Period2019202020212022202320242025TTM
Sales, quarterly1.143000000021
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual28.66428.66427.31331.43439.10744.82748.59748.599
Period2019202020212022202320242025MRQ
Shares, quarterly43.70243.72244.82744.82745.33547.27448.59748.59748.599
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue21.000.001.8919.9416.400.000.000.00
Cost of Goods Sold Incl. D&A3.651.631.811.762.510.730.780.46
Gross Profit17.35-1.630.0718.1813.89-0.73-0.78-0.46
Selling, General and Administrative Excl. Other42.9259.0473.6758.6869.9549.3521.639.47
Research and Development29.4344.8356.4341.7853.7635.2716.646.34
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-25.57-60.68-73.59-40.50-56.06-50.09-22.40-9.94
Interest Expense4.555.274.663.140.000.000.000.37
Unusual Expense6.45-2.07-1.071.03-0.560.00-7.30-0.12
Net Income Before Taxes-34.61-60.82-70.52-37.37-53.81-49.98-15.04-10.25
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-34.61-60.82-70.52-37.37-53.81-49.98-15.04-10.25
Net Income From Continuing Operations-34.61-60.82-70.52-37.37-53.81-49.98-15.04-10.25
Net Income-34.61-60.82-70.52-37.37-53.81-201.93-28.22-18.23
EPS (Recurring)-0.63-1.36-1.65-1.03-1.88-7.39-1.16-0.64
EPS (Basic, Before Extraordinaries)-0.73-1.32-1.63-1.05-1.86-7.39-0.98-0.64
EPS (Diluted)-0.74-1.33-1.63-1.05-1.86-7.39-0.98-0.64
EBITDA-21.92-59.04-71.78-38.74-53.55-49.35-21.63-9.47
Non-Operating Income (Expense)1.963.066.677.301.690.100.06-0.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.546.258.838.017.404.090.630.56
Price To Sales Ratio0.83-34.446.903.61---
Gross Margin82.61-3.7791.1584.70---
Operating Margin-121.78--3,904.19-203.09-341.78---
Net Margin-164.82--3,740.85-187.37-328.09---
Shares Outstanding48.6048.6044.8339.1131.4327.3128.6628.66
Market Capitalization47.1447.1465.95139.7063.03328.47336.19-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue21.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A2.450.400.400.400.410.430.440.45
Gross Profit18.55-0.40-0.40-0.40-0.41-0.43-0.44-0.45
Selling, General and Administrative Excl. Other10.018.579.0215.3217.1417.5719.9116.67
Research and Development5.745.126.9311.6313.1413.1215.7312.53
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income8.54-8.97-9.42-15.73-17.54-17.99-20.35-17.12
Interest Expense0.471.371.371.341.301.261.271.24
Unusual Expense4.703.63-1.85-0.03-0.02-0.17-3.340.10
Net Income Before Taxes3.67-13.53-8.38-16.37-17.98-18.09-20.40-16.67
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income3.67-13.53-8.38-16.37-17.98-18.09-20.40-16.67
Net Income From Continuing Operations3.67-13.53-8.38-16.37-17.98-18.09-20.40-16.67
Net Income3.67-13.53-8.38-16.37-17.98-18.09-20.40-16.67
EPS (Recurring)0.14-0.23-0.20-0.36-0.40-0.41-0.51-0.38
EPS (Basic, Before Extraordinaries)0.08-0.28-0.17-0.36-0.40-0.40-0.46-0.38
EPS (Diluted)0.08-0.28-0.17-0.36-0.40-0.40-0.46-0.38
EBITDA10.99-8.57-9.02-15.32-17.14-17.57-19.91-16.67
Non-Operating Income (Expense)0.310.430.550.670.840.99-2.121.79
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.420.931.210.971.792.011.912.01
Price To Sales Ratio0.83----38.1334.9227.36
Gross Margin88.32-------
Operating Margin40.65-------
Net Margin17.48-------
Shares Outstanding48.6048.6048.6047.2745.3444.8344.8343.72
Market Capitalization47.1440.4630.7590.0948.9143.5865.9592.65

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments57.05111.00134.34129.31157.6392.5717.90
Short Term Receivables0.000.001.356.930.000.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets1.542.072.683.963.440.340.17
Total Current Assets58.59113.07138.37140.20161.0792.9118.06
Net Property, Plant & Equipment9.9012.3214.8517.4516.323.123.41
Total Investments and Advances0.901.2221.021.211.210.210.21
Intangible Assets-----0.000.00
Deferred Tax Assets-2.57-----
Other Assets0.010.320.591.380.650.150.00
Total Assets69.40129.50174.83160.25179.2596.4021.68
Short Term Debt Incl. Current Port. of LT Debt29.991.568.282.081.070.680.59
Accounts Payable0.753.041.341.222.041.020.63
Other Current Liabilities5.4110.599.7720.688.773.590.82
Total Current Liabilities36.1515.1819.3823.9911.875.282.04
Long Term Debt7.6835.5343.6512.6014.591.869.84
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities-2.57-----
Other Liabilities0.762.830.431.320.000.030.02
Total Liabilities44.5956.1163.4637.9126.467.1811.91
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00141.0834.07
Common Equity24.8073.39111.37122.34152.79-51.86-24.30
Total Shareholders Equity24.8073.39111.37122.34152.7989.229.77
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity24.8073.39111.37122.34152.7989.229.77
Total Liabilities & Stockholders Equity69.40129.50174.83160.25179.2596.4021.68
Book Value Per Share0.511.642.853.895.59-1.81-0.85
Tangible Book Value Per Share0.511.642.853.895.59-1.81-0.85
Full-Time Employees394647463924-
Price to Book Ratio2.890.721.220.482.131.96-
Return on Assets-61.16-46.34-22.30-31.70-36.27-25.47-
Return on Equity-123.88-76.33-31.98-39.12-41.31-30.39-
Return on Invested Capital-187.21-64.74-24.10-39.88-29.86-16.51-52.25
Quick Ratio1.627.457.145.8413.5617.588.84
Current Ratio1.627.457.145.8413.5617.588.84

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-34.61-60.82-70.52-37.37-53.81-49.98-15.04-10.25
Depreciation3.651.631.811.762.510.730.780.46
Other Funds (Non Cash)6.197.109.998.898.084.09-6.670.95
Funds from Operations-24.77-52.09-58.71-26.72-43.22-45.15-20.93-8.83
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-5.38-8.212.53-5.892.542.282.31-0.71
Cash from Operating Activities-30.15-60.29-56.19-32.61-40.68-42.88-18.62-9.54
Capital Expenditures0.000.00-0.25-0.77-3.61-0.50-0.56-0.27
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.420.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities0.420.00-0.25-0.77-3.61-0.50-0.56-0.27
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock5.646.0323.7558.4315.99109.4394.0121.91
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock5.646.0323.7558.4315.99109.4394.0121.91
Proceedsfrom Stock Options5.646.0323.7258.4215.74109.2293.9921.91
Issuance or Reduction of Debt, Net-32.410.00-10.670.000.000.000.000.00
Change in Long Term Debt-32.410.00-10.670.000.000.000.000.00
Issuance of Long Term Debt0.000.0029.330.000.000.000.000.00
Reduction of Long Term Debt-32.410.00-40.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities-26.776.0313.0858.4315.99109.4393.8621.91
Net Change in Cash-56.50-54.26-43.3625.05-28.3066.0574.6712.10
Free Cash Flow-30.15-60.29-56.44-33.38-44.30-43.37-19.18-9.81
Preferred Dividends (Cash Flow)-0.000.000.000.00---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments21.9946.4557.0565.7177.6092.04
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.912.281.542.462.842.42
Total Current Assets22.8948.7358.5968.1780.4494.46
Net Property, Plant & Equipment1.269.299.9010.5111.1111.71
Total Investments and Advances0.000.000.900.900.900.89
Intangible Assets0.000.00----
Other Assets0.000.000.010.050.120.18
Total Assets24.1658.0269.4079.6392.57107.24
Short Term Debt Incl. Current Port. of LT Debt0.0030.4329.997.503.851.41
Accounts Payable1.943.570.751.082.770.99
Other Current Liabilities5.924.515.419.028.549.27
Total Current Liabilities7.8638.5236.1517.6015.1711.67
Long Term Debt0.007.227.6829.8033.2935.60
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.090.762.612.642.66
Total Liabilities7.8645.8244.5950.0151.1049.93
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity16.2912.2024.8029.6141.4657.31
Total Shareholders Equity16.2912.2024.8029.6141.4657.31
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity16.2912.2024.8029.6141.4657.31
Total Liabilities & Stockholders Equity24.1658.0269.4079.6392.57107.24
Book Value Per Share0.340.250.510.630.911.28
Tangible Book Value Per Share0.340.250.510.630.911.28
Full-Time Employees-1439-4646
Price to Book Ratio2.891.631.012.150.850.59
Return on Assets-59.31-68.09-61.16-66.32-59.40-50.84
Return on Equity-119.86-161.89-123.88-122.43-100.55-82.81
Return on Invested Capital22.53-69.69-25.80-27.55-24.05-19.47
Quick Ratio2.911.271.623.875.308.09
Current Ratio2.911.271.623.875.308.09

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income3.67-13.53-8.38-16.37-17.98-18.09
Depreciation2.450.400.400.400.410.43
Other Funds (Non Cash)3.021.070.141.962.492.51
Funds from Operations9.14-12.07-7.84-14.01-15.09-15.15
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-2.521.47-3.19-1.15-0.07-3.80
Cash from Operating Activities6.63-10.60-11.02-15.16-15.16-18.95
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.420.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.420.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.002.373.270.390.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.002.373.270.390.00
Proceedsfrom Stock Options0.000.002.373.270.390.00
Issuance or Reduction of Debt, Net-32.410.000.000.000.000.00
Change in Long Term Debt-32.410.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-32.410.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-32.410.002.373.270.390.00
Net Change in Cash-25.37-10.60-8.66-11.88-14.78-18.95
Free Cash Flow6.63-10.60-11.02-15.16-15.16-18.95

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.33%2.1M39.9M6.63M
2026-10-155.90%2.4M39.9M6.69M
2026-09-306.29%2.5M39.9M6.86M
2026-09-154.02%1.7M42.5M7.02M
2026-08-313.93%1.7M42.5M6.85M
2026-08-142.51%1.1M42.5M720.93K
2026-07-312.59%1.1M42.5M788.09K
2026-07-152.20%0.9M42.5M690.68K
2026-06-302.00%0.8M42.3M595.08K
2026-06-152.29%1.0M42.2M456.51K
2026-05-292.26%0.9M42.0M455.02K
2026-05-151.61%0.7M41.5M447.42K
2026-04-301.76%0.7M41.2M385.35K
2026-04-151.95%0.8M40.4M421.34K
2026-03-313.42%1.4M40.4M441.15K
2026-03-133.47%1.4M40.4M631.40K
2026-02-275.13%2.1M40.4M622.41K
2026-02-135.08%2.1M40.4M618.62K
2026-01-305.99%2.4M40.4M686.23K
2026-01-155.66%2.3M40.4M720.07K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.200.650.468.3646811.000.955-0.0150.000
call1.000.000.200.113.3064720.000.669-0.0180.001
call1.500.000.050.042.79911.000.000.236-0.0070.000
call2.000.000.600.003.8280.000.000.195-0.0090.000
call2.500.000.600.004.4570.000.000.176-0.0090.000
call5.000.000.600.006.3180.000.000.143-0.0120.000
call7.500.000.050.007.2860.000.000.132-0.0130.000
put0.500.000.400.0018.5310.000.00-0.045-0.0150.000
put1.000.000.500.008.5200.000.00-0.331-0.0180.001
put1.500.300.900.008.4020.000.00-0.764-0.0070.000
put2.000.751.400.009.6830.000.00-0.805-0.0090.000
put2.501.201.900.009.1630.000.00-0.824-0.0090.000
put5.003.704.400.0012.0900.000.00-0.857-0.0110.000
put7.506.207.000.0015.5130.000.00-0.869-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10S-4/ASEC
2026-11-10425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-10-26S-4/ASEC
2026-09-22S-4Registration statement for securities to be issued in business combination transactionsSEC
2026-09-21SCHEDULE 13GSEC
2026-08-21425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-08-218-KCurrent report2026-08-21SEC
2026-08-208-KCurrent report2026-08-14SEC
2026-07-3110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-318-KCurrent report2026-07-31SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-07-06144Filing for proposed sale of securities under Rule 144.SEC
2026-07-06144Filing for proposed sale of securities under Rule 144.SEC
2026-07-06144Filing for proposed sale of securities under Rule 144.SEC
2026-07-06144Filing for proposed sale of securities under Rule 144.SEC
2026-07-06144Filing for proposed sale of securities under Rule 144.SEC
2026-07-06144Filing for proposed sale of securities under Rule 144.SEC
2026-07-02SCHEDULE 13D/ASEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-06-26SCHEDULE 13D/ASEC
2026-06-22SCHEDULE 13D/ASEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-12SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070044.75K2
2026-0600708.37K14
2026-05001.07M21
2026-0400275.67K4
2026-030000
2026-020000
2026-0100193.84K11
2025-12001.09M28
2025-11003.34M57

Institutional holders

Manager% owned
RA CAPITAL MANAGEMENT, L.P.4.91%
BALYASNY ASSET MANAGEMENT L.P.3.68%
VANGUARD CAPITAL MANAGEMENT LLC2.51%
RENAISSANCE TECHNOLOGIES LLC1.39%
Lynx1 Capital Management LP1.35%
SPHERA FUNDS MANAGEMENT LTD.1.29%
DC Funds, LP1.21%
GEODE CAPITAL MANAGEMENT, LLC0.84%
Verdad Advisers, LP0.72%
ACADIAN ASSET MANAGEMENT LLC0.65%

Funds

Fund% owned
Select Biotechnology Portfolio16.96%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.80%
VANGUARD EXTENDED MARKET INDEX FUND0.71%
Fidelity Extended Market Index Fund0.42%
Fidelity Total Market Index Fund0.11%
Fidelity Series Total Market Index Fund0.09%
Fidelity Nasdaq Composite Index Fund0.02%
Blackstone Alternative Multi-Strategy Fund0.00%
Guggenheim Active Allocation Fund0.00%

OakChart. HOWL. Cached 15 minutes.